Literature DB >> 24981047

Outcomes and complications of trans-vaginal mesh repair using the Prolift™ kit for pelvic organ prolapse at 4 years median follow-up in a tertiary referral centre.

Zainab A Khan1, Lee Thomas, Simon J Emery.   

Abstract

PURPOSE: To evaluate the anatomical, functional and post-operative outcomes of polypropylene mesh (Prolift™) in the surgical management of pelvic organ prolapse (POP).
METHODS: A single-centre observational study of 106 successive patients, who underwent Prolift™ mesh repair (POP ≥ 2) with a median follow-up of 4 years, was performed. Outcomes of interest measured included patient demographics, intra and post-operative complications, concomitant procedures for POP or urinary incontinence. Using the Baden-Walker classification, grade ≥2 prolapses in the operated compartment were deemed as surgical failure. Validated questionnaires including ICIQ-VS and ICIQ-UI were used to assess functional outcome.
RESULTS: Of the 106 patients, 56 had an anterior, 36 a posterior and 14 a total Prolift™. 101 patients were available for follow-up (median 4 years). 82 women underwent a clinical follow-up whilst 19 underwent a telephonic follow-up. Peri-operative bladder injury was noted in 2 (1.9 %) cases. Six (5.6 %) patients developed mesh exposure post-operatively. Re-operation rates for recurrent prolapse in the operated compartment were 2.8 % (n = 3). At follow-up, prolapse recurrence in the operated compartment was noted in another 7.3 % (n = 6) patients. Combining re-operations for POP and recurrences noted during follow-up, the revised failure rate was 10.1 % (n = 9). De novo prolapse in the non-operated compartment occurred in 19.5 % (n = 16) women.
CONCLUSION: Our study demonstrates that Prolift™ vaginal mesh surgery offers anatomical cure rates of 89.9 %. A higher rate of de novo recurrence in the non-operated compartment was noted suggesting that surgical correction in one compartment may exacerbate recurrence in other compartments.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24981047     DOI: 10.1007/s00404-014-3316-3

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  7 in total

1.  Synthetic Graft Augmentation in Vaginal Prolapse Surgery: Long-Term Objective and Subjective Outcomes.

Authors:  Isuzu Meyer; Gerald McGwin; Thomas A Swain; Mitchell D Alvarez; David R Ellington; Holly E Richter
Journal:  J Minim Invasive Gynecol       Date:  2016-02-23       Impact factor: 4.137

2.  Pelvic organ prolapse repair using the Uphold™ Vaginal Support System: a 1-year multicenter study.

Authors:  Daniel Altman; Tomi S Mikkola; Karl Möller Bek; Päivi Rahkola-Soisalo; Jonas Gunnarsson; Marie Ellström Engh; Christian Falconer
Journal:  Int Urogynecol J       Date:  2016-02-13       Impact factor: 2.894

Review 3.  Comparison of synthetic mesh erosion and chronic pain rates after surgery for pelvic organ prolapse and stress urinary incontinence: a systematic review.

Authors:  Eoin MacCraith; Eoghan M Cunnane; Michael Joyce; James C Forde; Fergal J O'Brien; Niall F Davis
Journal:  Int Urogynecol J       Date:  2020-11-25       Impact factor: 2.894

4.  Subjective and Objective Evaluation of Total Pelvic Floor Reconstruction with Six-Arm Mesh in Patients with Severe Pelvic Organ Prolapse: A 1-Year Retrospective Study.

Authors:  Ying Zhao; Zhi-Jun Xia; Qing Hu; Mei-Ying Qin
Journal:  Ther Clin Risk Manag       Date:  2020-09-14       Impact factor: 2.423

Review 5.  Vaginal Approaches Using Synthetic Mesh to Treat Pelvic Organ Prolapse.

Authors:  Jei Won Moon; Hee Dong Chae
Journal:  Ann Coloproctol       Date:  2016-02-29

6.  Management of Urinary Incontinence before and after Total Pelvic Reconstruction for Advanced Pelvic Organ Prolapse with and without Incontinence.

Authors:  Yu Song; Xiao-Juan Wang; Yi-Song Chen; Ke-Qin Hua
Journal:  Chin Med J (Engl)       Date:  2018-03-05       Impact factor: 2.628

7.  Clinical efficacy of pelvic autologous tissue reconstruction in treating pelvic organ prolapse in 36 patients.

Authors:  Ling-Xiao Huang; Ren-Liang Li; Li-Xiao Sha; Xiao-Hua Lin
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.